Mallinckrodt (MNKTQ) 10-Q 9 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 05, 2023
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-35803
Entity Registrant Name	Mallinckrodt plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1088325
Entity Address, Address Line One	College Business & Technology Park
Entity Address, City or Town	Dublin
Entity Address, Postal Zip Code	15
Entity Address, Country	IE
City Area Code	1
Local Phone Number	696 0000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Central Index Key	0001567892
Current Fiscal Year End Date	--12-29
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Ordinary Shares Outstanding		13,170,932
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Address, Address Line Two	Cruiserath
Entity Address, Address Line Three	Blanchardstown
Country Region	353
Entity Filer Category	Accelerated Filer
Title of 12(b) Security	Ordinary shares, par value $0.01 per share
Trading Symbol	MNK
Security Exchange Name	NYSEAMER

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Net sales	$ 424.6	$ 490.9
Cost of sales	374.8	315.2
Gross profit	49.8	175.7
Selling, general and administrative expenses	122.9	152.5
Research and development expenses	28.3	37.2
Restructuring charges, net	1.2	6.8
Operating loss	(102.6)	(20.8)
Interest expense	162	58.2
Interest income	(4.7)	(0.4)
Other expense, net	(14.6)	(4.1)
Reorganization items, net	(5.6)	(43.4)
Loss from continuing operations before income taxes	(280.1)	(126.1)
Income tax benefit	(30.8)	(5.9)
Loss from continuing operations	(249.3)	(120.2)
Income from discontinued operations, net of income taxes	0	0.6
Net loss	$ (249.3)	$ (119.6)
Basic (loss) income per share (Note 5):
Loss from continuing operations	$ (18.93)	$ (1.42)
Income from discontinued operations	0	0.01
Net loss	$ (18.93)	$ (1.41)
Basic weighted-averaged shares outstanding (in shares)	13.2	84.7
Diluted (loss) income per share (Note 5):
Loss from continuing operations	$ (18.93)	$ (1.42)
Income from discontinued operations	0	0.01
Net loss	$ (18.93)	$ (1.41)
Diluted weighted-average shares outstanding (in shares)	13.2	84.7
Retained Earnings (Deficit)
Net loss	$ (249.3)	$ (119.6)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Net loss	$ (249.3)	$ (119.6)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(2.6)	0
Currency translation adjustments	1.8	0.2
Derivatives, net of tax	(4.3)	0
Benefit plans, net of tax	(0.1)	(0.2)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(251.9)	(119.6)
Net loss	(249.3)	(119.6)
Other comprehensive loss, net of tax:
Currency translation adjustments	1.8	0.2
Derivatives, net of tax	(4.3)	0
Benefit plans, net of tax	(0.1)	(0.2)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(2.6)	0
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total	(251.9)	(119.6)
Retained Earnings (Deficit)
Net loss	(249.3)	(119.6)
Net loss	(249.3)	$ (119.6)
Accumulated Other Comprehensive Loss
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(2.6)
Other comprehensive loss, net of tax:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ (2.6)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets $ in Millions	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 30, 2022 USD ($) $ / shares shares
Cash and cash equivalents	$ 480	$ 409.5
Accounts receivable, less allowance for doubtful accounts of $5.1 and $4.4	395.1	405.3
Inventories	895.4	947.6
Prepaid expenses and other current assets	120.7	273.4
Assets, Current	1,891.2	2,035.8
Property, plant and equipment, net	454.4	457.6
Intangible assets, net	2,710.6	2,843.8
Other assets	205.2	201.1
Assets	5,770.8	6,013.8
Current maturities of long-term debt	44.1	44.1
Accounts payable	86.4	114
Accrued payroll and payroll-related costs	35.4	49.5
Accrued interest	76.8	29
Medicaid lawsuit liability	16.5	16.5
Opioid-Related Litigation Settlement liability, Current	200	200
Accrued and other current liabilities	234.5	290.7
Liabilities, Current	693.7	743.8
Long-term debt	3,041.6	3,027.7
Opioid-Related Litigation Settlement liability	419.6	379.9
Acthar Gel-Related Settlement, Non-current	81.2	75
Pension and postretirement benefits	41.2	41
Environmental liabilities	35.6	35.8
Other income tax liabilities	18.5	18.2
Other liabilities	75	78.7
Liabilities	4,406.4	4,400.1
Preferred shares	0	0
Ordinary A shares	0	0
Ordinary shares	$ 0.1	$ 0.1
Preferred shares, par value (in usd per share) | $ / shares	$ 0.01	$ 0.01
Preferred shares, shares authorized (in shares) | shares	500,000,000	500,000,000
Preferred shares, shares issued (in shares) | shares	0	0
Preferred shares, shares outstanding (in shares) | shares	0	0
Deferred Tax Assets, Net	$ 509.4	$ 475.5
Ordinary shares, shares issued (in shares) | shares	13,170,932	13,170,932
Ordinary shares, shares authorized (in shares) | shares	500,000,000	500,000,000
Common Stock, Shares, Outstanding | shares	13,170,932	13,170,932
Ordinary shares, par value (in usd per share) | $ / shares	$ 0.01	$ 0.01
Additional Paid in Capital	$ 2,193.6	$ 2,191
Accumulated Other Comprehensive Income (Loss), Net of Tax	8.2	10.8
Retained deficit	(837.5)	(588.2)
Stockholders' Equity Attributable to Parent	1,364.4	1,613.7
Liabilities and Equity	5,770.8	6,013.8
Current Assets:
Cash and cash equivalents	480	409.5
Accounts receivable, less allowance for doubtful accounts of $5.1 and $4.4	395.1	405.3
Inventories	895.4	947.6
Prepaid expenses and other current assets	120.7	273.4
Total current assets	1,891.2	2,035.8
Property, plant and equipment, net	454.4	457.6
Intangible assets, net	2,710.6	2,843.8
Other assets	205.2	201.1
Total Assets	5,770.8	6,013.8
Current Liabilities:
Current maturities of long-term debt	44.1	44.1
Accounts payable	86.4	114
Accrued payroll and payroll-related costs	35.4	49.5
Accrued interest	76.8	29
Accrued and other current liabilities	234.5	290.7
Total current liabilities	693.7	743.8
Pension and postretirement benefits	41.2	41
Environmental liabilities	35.6	35.8
Other income tax liabilities	18.5	18.2
Other liabilities	75	78.7
Total Liabilities and Shareholders' Equity	5,770.8	6,013.8
Other liabilities	4,406.4	4,400.1
Shareholders' Equity:
Preferred shares	$ 0	$ 0
Preferred shares, shares outstanding (in shares) | shares	0	0
Ordinary A shares	$ 0	$ 0
Ordinary shares	0.1	0.1
Additional Paid in Capital	2,193.6	2,191
Retained deficit	(837.5)	(588.2)
Accumulated Other Comprehensive Income (Loss), Net of Tax	8.2	10.8
Total Shareholders' Equity	$ 1,364.4	$ 1,613.7
Ordinary A
Ordinary shares, shares issued (in shares) | shares	0	0
Ordinary shares, shares authorized (in shares) | shares	40,000	40,000
Shareholders' Equity:
Ordinary A shares, shares outstanding (in shares) | shares	0	0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2023 € / shares	Dec. 30, 2022 USD ($) $ / shares shares	Dec. 30, 2022 € / shares
Allowance for doubtful accounts | $	$ 5.1		$ 4.4
Preferred shares, par value (in usd per share) | $ / shares	$ 0.01		$ 0.01
Preferred shares, shares authorized (in shares)	500,000,000		500,000,000
Preferred shares, shares issued (in shares)	0		0
Preferred shares, shares outstanding (in shares)	0		0
Ordinary shares, par value (in usd per share) | $ / shares	$ 0.01		$ 0.01
Ordinary shares, shares authorized (in shares)	500,000,000		500,000,000
Ordinary shares, shares issued (in shares)	13,170,932		13,170,932
Ordinary shares, shares outstanding (in shares)	13,170,932		13,170,932
Ordinary A
Ordinary shares, par value (in usd per share) | € / shares		€ 1		€ 1
Ordinary shares, shares authorized (in shares)	40,000		40,000
Ordinary shares, shares issued (in shares)	0		0
Ordinary A shares, shares outstanding (in shares)	0		0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 0.3	$ (0.7)
Net loss	(249.3)	(119.6)
Depreciation and amortization	145.1	177.2
Share-based compensation		1.2
Deferred income taxes	(33.4)	(0.9)
Reorganization Items, non-cash	0	2.9
Accretion Expense	69.9	0
Other Noncash Income (Expense)	(20)	(12.3)
Increase (Decrease) in Accounts Receivable	(9.6)	(73.8)
Increase (Decrease) in Inventories	(48)	27
Accounts payable	(20.4)	0.4
Income taxes	138.9	(7.8)
Increase (Decrease) in Other Operating Assets and Liabilities, Net	31.1	63.3
Net Cash Provided by (Used in) Operating Activities	99.9	49.2
Payments to Acquire Property, Plant, and Equipment	19.3	23.6
Payments for (Proceeds from) Other Investing Activities	(0.3)	(0.2)
Net Cash Provided by (Used in) Investing Activities	(19)	(23.4)
Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security	11	4.6
Net Cash Provided by (Used in) Financing Activities	(11)	(4.6)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	70.2	20.5
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	536.9	1,425.7
Cash and cash equivalents	480	1,365.3
Restricted Cash and Investments, Current	21.5	24
Restricted Cash and Investments, Noncurrent	35.4	36.4
Cash Flows From Operating Activities:
Net loss	(249.3)	(119.6)
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization	145.1	177.2
Share-based compensation		1.2
Deferred income taxes	(33.4)	(0.9)
Reorganization Items, non-cash	0	2.9
Other non-cash items	20	12.3
Changes in assets and liabilities:
Accounts receivable, net	9.6	73.8
Inventories	48	(27)
Accounts payable	(20.4)	0.4
Income taxes	138.9	(7.8)
Other	(31.1)	(63.3)
Net Cash From Operating Activities	99.9	49.2
Cash Flows From Investing Activities:
Capital expenditures	(19.3)	(23.6)
Other	0.3	0.2
Net Cash From Investing Activities	(19)	(23.4)
Cash Flows From Financing Activities:
Repayment of external debt	(11)	(4.6)
Net Cash Provided From Financing Activities	(11)	(4.6)
Net change in cash, cash equivalents and restricted cash	70.2	20.5
Cash, cash equivalents and restricted cash at beginning of period	466.7	1,405.2
Cash, cash equivalents and restricted cash at end of period	536.9	1,425.7
Cash and cash equivalents, end of period	480	1,365.3
Restricted Cash and Investments, Current	21.5	24
Restricted Cash and Investments, Noncurrent	35.4	36.4
Retained Earnings (Deficit)
Net loss	(249.3)	(119.6)
Cash Flows From Operating Activities:
Net loss	(249.3)	$ (119.6)
Additional Paid-In Capital
Share-based compensation	2.6
Adjustments to reconcile net cash from operating activities:
Share-based compensation	$ 2.6

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Changes in Shareholders' Equity Statement - USD ($) $ in Millions	Total	Ordinary Shares	Additional Paid-In Capital	Retained Earnings (Deficit)	Accumulated Other Comprehensive Loss	Treasury Stock, Common
Shares, Outstanding		94,300,000				9,600,000
Beginning balance at Dec. 31, 2021	$ 313.4	$ 18.9	$ 5,597.8	$ (3,678.9)	$ (8.3)	$ (1,616.1)
Net loss	(119.6)			(119.6)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	0
Share-based compensation	1.2		1.2
Ending balance at Apr. 01, 2022	$ 195	$ 18.9	5,599	(3,798.5)	(8.3)	$ (1,616.1)
Shares, Outstanding		94,300,000				9,600,000
Shares, Outstanding		13,200,000				0
Beginning balance, ordinary shares (in shares) at Dec. 30, 2022	13,170,932
Beginning balance at Dec. 30, 2022	$ 1,613.7	$ 0.1	2,191	(588.2)	10.8	$ 0
Net loss	(249.3)			(249.3)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(2.6)				(2.6)
Share-based compensation	$ 2.6
Ending balance, ordinary shares (in shares) at Mar. 31, 2023	13,170,932
Ending balance at Mar. 31, 2023	$ 1,364.4	$ 0.1	$ 2,193.6	$ (837.5)	$ 8.2	$ 0
Shares, Outstanding		13,200,000				0

Background and Basis of Present

Background and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation	1. Background and Basis of Presentation Background Mallinckrodt plc is a global business of multiple wholly owned subsidiaries (collectively, "Mallinckrodt" or "the Company") that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. The Company operates in two reportable segments, which are further described below: • Specialty Brands includes innovative specialty pharmaceutical brands; and • Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients ("API(s)"). The Company owns or has rights to use the trademarks and trade names that are used in conjunction with the operation of its business. One of the more important trademarks that the Company owns or has rights to use that appears in this Quarterly Report on Form 10-Q is "Mallinckrodt," which is a registered trademark or the subject of pending trademark applications in the United States ("U.S.") and other jurisdictions. Solely for convenience, the Company only uses the ™ or ® symbols the first time any trademark or trade name is mentioned in the following notes. Such references are not intended to indicate in any way that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks and trade names. Each trademark or trade name of any other company appearing in the following notes is, to the Company's knowledge, owned by such other company. Basis of Presentation On October 12, 2020 ("Petition Date"), Mallinckrodt plc and substantially all of its U.S. subsidiaries, including certain subsidiaries of Mallinckrodt plc operating the Specialty Generics business ("Specialty Generics Subsidiaries") and the Specialty Brands business ("Specialty Brands Subsidiaries"), and certain of the Company's international subsidiaries (together with the Company, Specialty Generics Subsidiaries and Specialty Brands Subsidiaries, the "Debtors") voluntarily initiated proceedings ("Chapter 11 Cases") under chapter 11 of title 11 ("Chapter 11") of the United States Code ("Bankruptcy Code"). On March 2, 2022, the U.S. Bankruptcy Court for the District of Delaware ("Bankruptcy Court") entered an order confirming the fourth amended plan of reorganization (with technical modifications) ("Plan"). Subsequent to the filing of the Chapter 11 Cases, Chapter 11 proceedings commenced by a limited subset of the Debtors were recognized and given effect in Canada, and separately the High Court of Ireland made an order confirming a scheme of arrangement on April 27, 2022, which is based on and consistent in all respects with the Plan ("Scheme of Arrangement"). On June 8, 2022, the Bankruptcy Court entered an order approving a minor modification to the Plan. The Plan became effective on June 16, 2022 ("Effective Date"), and on such date the Company emerged from the Chapter 11 and the Scheme of Arrangement became effective concurrently. Upon emergence from Chapter 11, the Company adopted fresh-start accounting in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 852 - Reorganizations , and became a new entity for financial reporting purposes as of the Effective Date. References to "Successor" relate to the financial position as of June 16, 2022 and results of operations of the reorganized Company subsequent to June 16, 2022, while references to "Predecessor" relate to the financial position prior to June 16, 2022 and results of operations of the Company prior to, and including, June 16, 2022. All emergence-related transactions of the Predecessor were recorded as of June 16, 2022. Accordingly, the unaudited condensed consolidated financial statements for the Successor are not comparable to the unaudited condensed consolidated financial statements for the Predecessor. Reorganization items, net for the Successor represents amounts incurred after the Effective Date that directly resulted from Chapter 11 and were entirely comprised of professional fees associated with the implementation of the Plan. Reorganization items, net for the Predecessor represents amounts incurred after the Petition Date but prior to emergence as a direct result of the Chapter 11 Cases and were comprised of bankruptcy-related professional fees and adjustments to reflect the carrying value of liabilities subject to compromise ("LSTC") at their estimated allowed claim amounts, as such adjustments were approved by the Bankruptcy Court. Cash paid for reorganization items, net for the three months ended March 31, 2023 (Successor) and April 1, 2022 (Successor) was $9.4 million and $79.1 million, respectively. The Company also reassessed and updated its product line net sales presentation for its Specialty Generics segment. Beginning with the Quarterly Report on Form 10-Q for the quarterly period ended July 1, 2022 (Successor), the Company's unaudited condensed consolidated financial statements reflect the updated product line net sales structure for its Specialty Generics segment. Prior year amounts have been recast to conform to current presentation. The unaudited condensed consolidated financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and entities in which they own or control more than 50.0% of the voting shares, or have the ability to control through similar rights. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows and financial position have been made. All intercompany balances and transactions have been eliminated in consolidation and all normal recurring adjustments necessary for a fair presentation have been included in the results reported. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The results of entities disposed of are included in the unaudited condensed consolidated financial statements up to the date of disposal, and where appropriate, these operations have been reported in discontinued operations. Divestitures of product lines and businesses not meeting the criteria for discontinued operations have been reflected in operating loss. The fiscal year end balance sheet data was derived from audited consolidated financial statements, but does not include all of the annual disclosures required by GAAP; accordingly these unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited annual consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended December 30, 2022 filed with the U.S. Securities and Exchange Commission ("SEC") on March 3, 2023 ("Annual Report on Form 10-K"). Fiscal Year The Company reports its results based on a "52-53 week" year ending on the last Friday of December. Unless otherwise indicated, the three months ended March 31, 2023 (Successor) refers to the thirteen week period ended March 31, 2023 (Successor) and the three months ended April 1, 2022 (Predecessor) refers to the thirteen week period ended April 1, 2022 (Predecessor).

Revenue from Contracts with Cus

Revenue from Contracts with Customers Revenue from Contracts with Customers (Notes)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	2. Revenue from Contracts with Customers Product Sales Revenue See Note 13 for presentation of the Company's net sales by product family. Reserves for variable consideration The following table reflects activity in the Company's sales reserve accounts: Rebates and Chargebacks (1) Product Returns Other Sales Deductions Total Balance as of December 31, 2021 (Predecessor) $ 241.8 $ 21.5 $ 9.5 $ 272.8 Provisions 370.8 2.4 9.7 382.9 Payments or credits (412.0) (4.3) (10.0) (426.3) Balance as of April 1, 2022 (Predecessor) $ 200.6 $ 19.6 $ 9.2 $ 229.4 Balance as of December 30, 2022 (Successor) $ 265.3 $ 16.0 $ 12.7 $ 294.0 Provisions 355.6 3.2 9.5 368.3 Payments or credits (404.3) (4.0) (15.0) (423.3) Balance as of March 31, 2023 (Successor) $ 216.6 $ 15.2 $ 7.2 $ 239.0 (1) Includes $58.9 million and $89.3 million of accrued Medicaid and $44.6 million and $55.3 million of accrued rebates as of March 31, 2023 (Successor) and December 30, 2022 (Successor), respectively, included within accrued and other current liabilities in the unaudited condensed consolidated balance sheets. Product sales transferred to customers at a point in time and over time were as follows: Successor Predecessor Three Months Three Months Product sales transferred at a point in time 80.2 % 79.5 % Product sales transferred over time 19.8 20.5 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of March 31, 2023 (Successor): Remainder of Fiscal 2023 $ 56.6 Fiscal 2024 37.7 Fiscal 2025 13.2 Thereafter 0.2 Product Royalty Revenues The Company licenses certain rights to Amitiza ® (lubiprostone) ("Amitiza") to third parties in exchange for royalties on net sales of the product. The Company receives a double-digit royalty based on a percentage of the gross profits of the licensed products sold during the term of the agreements. The Company recognizes such royalty revenue as the related sales occur. The associated royalty revenue recognized was as follows: Successor Predecessor Three Months Three Months Royalty revenue $ 3.4 $ 20.0

Restructuring and Related Charg

Restructuring and Related Charges	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Related Charges	3. Restructuring and Related Charges During fiscal 2021 and 2018, the Company launched restructuring programs designed to improve its cost structure, neither of which has a specified time period. Charges of $50.0 million to $100.0 million were provided for under the 2021 program and $100.0 million to $125.0 million were provided for under the 2018 program. The 2021 program will commence upon substantial completion of the 2018 program, and has not commenced as of March 31, 2023 (Successor). Net restructuring and related charges by segment were as follows: Successor Predecessor Three Months Three Months Specialty Generics $ — $ 3.5 Corporate 1.9 3.3 Restructuring and related charges, net 1.9 6.8 Less: accelerated depreciation (0.7) — Restructuring charges, net $ 1.2 $ 6.8 Net restructuring and related charges by program were comprised of the following: Successor Predecessor Three Months Three Months 2018 Program $ 1.9 $ 6.8 Less: non-cash charges, including accelerated depreciation (0.8) (2.1) Total charges expected to be settled in cash $ 1.1 $ 4.7 The following table summarizes cash activity for restructuring reserves for the 2018 Program, which primarily related to employee severance and benefits: 2018 Program Balance as of December 30, 2022 (Successor) $ 4.6 Charges from continuing operations 1.2 Changes in estimate from continuing operations (0.1) Cash payments (4.2) Balance as of March 31, 2023 (Successor) $ 1.5 As of March 31, 2023 (Successor), net restructuring and related charges incurred cumulative to date for the 2018 Program were as follows: Successor Predecessor Specialty Brands $ — $ 3.1 Specialty Generics 0.8 18.5 Corporate 13.2 84.0 $ 14.0 $ 105.6 All of the restructuring reserves were included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets. Amounts paid in the future may differ from the amount currently recorded.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 16, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure	4. Income Taxes The Company's income tax expense (benefit) was as follows: Successor Predecessor Three Months Three Months Current tax expense (benefit) $ 2.6 $ (5.0) Deferred tax benefit (33.4) (0.9) Income tax benefit $ (30.8) $ (5.9) The Company recognized an income tax benefit of $30.8 million on a loss from continuing operations before income taxes of $280.1 million for the three months ended March 31, 2023 (Successor). This resulted in an effective tax rate of 11.0%. The income tax provision consisted of a deferred income tax benefit predominately related to intangible asset amortization, accretion expense associated with our settlement obligations and debt, inventory step-up amortization expense and other operating activity, partially offset by current income tax expense related to a decrease in prepaid income taxes. The income tax benefit of $30.8 million for the three months ended March 31, 2023 (Successor) consisted of $27.4 million attributed to pretax earnings in various jurisdictions, $2.1 million attributed to separation costs, reorganization items, net and restructuring charges, and $1.3 million attributed to the Coronavirus Aid, Relief, and Economic Security ("CARES") Act. The Company recognized an income tax benefit of $5.9 million on a loss from continuing operations before income taxes of $126.1 million for the three months ended April 1, 2022 (Predecessor). This resulted in an effective tax rate of 4.7%. The current and deferred income tax benefits were predominantly related to an increase to prepaid taxes and intangible asset amortization partially offset by utilization of loss carryforwards in non-valuation allowance jurisdictions. The income tax benefit of $5.9 million for the three months ended April 1, 2022 (Predecessor) consisted of $4.8 million attributed to pretax earnings in various jurisdictions and $1.9 million attributed to separation costs, reorganization items, net and restructuring charges, partially offset by $0.8 million attributed to the CARES Act. During the three months ended March 31, 2023 (Successor), net cash refunds for income taxes were $136.3 million, including refunds of $139.3 million received as a result of provisions in the CARES Act and net payments of $3.0 million related to operational activity. During the three months ended April 1, 2022 (Predecessor), net cash payments for income taxes were $2.7 million. The Company's unrecognized tax benefits, excluding interest, totaled $24.8 million as of both March 31, 2023 (Successor) and December 30, 2022 (Successor). If favorably settled, these balances would benefit the effective tax rate. The total amount of accrued interest and penalties related to these obligations was $3.1 million and $2.8 million as of March 31, 2023 (Successor) and December 30, 2022 (Successor), respectively. Within the next twelve months, the unrecognized tax benefits and the related interest and penalties are not expected to significantly change. Certain of the Company's subsidiaries continue to be subject to examination by taxing authorities. The earliest open years subject to examination for both the U.S federal and state jurisdictions and various foreign jurisdictions, including Ireland, Japan, Luxembourg, Switzerland and the United Kingdom is 2013.

Earnings per Share

Earnings per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share	5. Loss per Share Loss per share is computed by dividing net loss by the number of weighted-average shares outstanding during the period. Dilutive securities, including participating securities, have not been included in the computation of loss per share as the Company reported a net loss from continuing operations during all periods presented below and therefore, the impact would be anti-dilutive. The weighted-average number of shares outstanding used in the computations of both basic and diluted loss per share were as follows ( in millions ): Successor Predecessor Three Months Three Months Basic and diluted 13.2 84.7 The computation of diluted weighted-average shares outstanding for the three months ended March 31, 2023 (Successor) and April 1, 2022 (Predecessor) excluded approximately zero and 5.1 million shares of equity awards, respectively, because the effect would have been anti-dilutive.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2023
Inventory, Net [Abstract]
Inventories	6. Inventories Inventories were comprised of the following at the end of each period: Successor March 31, December 30, Raw materials and supplies $ 89.9 $ 80.2 Work in process 523.3 552.1 Finished goods 282.2 315.3 $ 895.4 $ 947.6

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment
Property, Plant and Equipment Disclosure	7. Property, Plant and Equipment The gross carrying amount and accumulated depreciation of property, plant and equipment were comprised of the following at the end of each period: Successor March 31, December 30, Property, plant and equipment, gross $ 492.5 $ 485.0 Less: accumulated depreciation (38.1) (27.4) Property, plant and equipment, net $ 454.4 $ 457.6 Depreciation expense was as follows: Successor Predecessor Three Months Three Months Depreciation expense $ 11.9 $ 22.1

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Intangible Assets The gross carrying amount and accumulated amortization of intangible assets were comprised of the following at the end of each period: Successor March 31, 2023 December 30, 2022 Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Completed technology $ 3,041.2 $ 451.9 $ 3,041.2 $ 318.7 Non-Amortizable: In-process research and development 121.3 121.3 Intangible asset amortization expense was as follows: Successor Predecessor Three Months Three Months Amortization expense $ 133.2 $ 155.1 The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows: Successor Remainder of Fiscal 2023 $ 376.0 Fiscal 2024 446.1 Fiscal 2025 385.1 Fiscal 2026 337.5 Fiscal 2027 284.4

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt Disclosure	9. Debt Debt was comprised of the following at the end of each period: Successor March 31, 2023 December 30, 2022 Principal Carrying Value Unamortized Discount and Debt Issuance Costs Principal Carrying Value Unamortized Discount and Debt Issuance Costs Current maturities of long-term debt: 2017 Replacement Term loan due September 2027 $ 34.8 $ 34.8 $ — $ 34.8 $ 34.8 $ — 2018 Replacement Term loan due September 2027 9.3 9.3 — 9.3 9.3 — Total current debt 44.1 44.1 — 44.1 44.1 — Long-term debt: 10.00% first lien senior secured notes due April 2025 495.0 478.0 — 495.0 475.9 — 10.00% second lien senior secured notes due April 2025 321.9 249.8 — 321.9 242.2 — 2017 Replacement Term loan due September 2027 1,330.6 1,186.6 — 1,339.3 1,187.3 — 2018 Replacement Term loan due September 2027 353.2 317.3 — 355.5 317.6 — 11.50% first lien senior secured notes due December 2028 650.0 650.0 19.9 650.0 650.0 20.8 10.00% second lien senior secured notes due June 2029 328.3 179.8 — 328.3 175.5 — Total long-term debt 3,479.0 3,061.5 19.9 3,490.0 3,048.5 20.8 Total debt $ 3,523.1 $ 3,105.6 $ 19.9 $ 3,534.1 $ 3,092.6 $ 20.8 Applicable interest rate As of March 31, 2023 (Successor), the applicable interest rate and outstanding principal on the Company's debt instruments were as follows: Applicable Interest Rate Outstanding Principal Fixed-rate instruments 10.54 % $ 1,795.2 2017 Replacement Term Loan due September 2027 (1) 9.94 1,365.4 2018 Replacement Term Loan due September 2027 (1) 10.19 362.5

Guarantees

Guarantees	3 Months Ended
	Mar. 31, 2023
Guarantees [Abstract]
Guarantees	10. Guarantees In disposing of assets or businesses, the Company has from time to time provided representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. The Company assesses the probability of potential liabilities related to such representations, warranties and indemnities and adjusts potential liabilities as a result of changes in facts and circumstances. The Company believes, given the information currently available, that the ultimate resolutions will not have a material adverse effect on its financial condition, results of operations and cash flows. In connection with the sale of the Specialty Chemical business (formerly known as Mallinckrodt Baker) in fiscal 2010, the Company agreed to indemnify the purchaser with respect to various matters, including certain environmental, health, safety, tax and other matters. The indemnification obligations relating to certain environmental, health and safety matters have a term of 17 years from the sale, while some of the other indemnification obligations have an indefinite term. The liability relating to all of these indemnification obligations was governed by a contract that was rejected as part of Chapter 11 and is no longer a liability of the Successor Company. The Company was required to pay $30.0 million into an escrow account as collateral to the purchaser. The contract governing the escrow account was assumed in the Chapter 11 proceedings. As of March 31, 2023 (Successor) and December 30, 2022 (Successor), $19.5 million and $19.3 million remained in restricted cash, included in other long-term assets on the unaudited condensed consolidated balance sheets, respectively. As of March 31, 2023 (Successor), the Company does not expect to make future payments related to these indemnification obligations.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company is subject to various legal proceedings and claims, including government investigations, environmental matters, product liability matters, patent infringement claims, antitrust matters, securities class action lawsuits, personal injury claims, employment disputes, contractual and other commercial disputes, and all other legal proceedings, all in the ordinary course of business, including those described below. Although it is not feasible to predict the outcomes of these matters, the Company believes, unless otherwise indicated below, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows. Governmental Proceedings Acthar Gel-Related Matters SEC Subpoena. In August 2019, the Company received a subpoena from the SEC for documents related to the Company's disclosure of its dispute with the U.S. Department of Health and Human Services ("HHS") and Centers for Medicare and Medicaid Services (together with HHS, the "Agency") concerning the base date average manufacturer price for Acthar Gel under the Medicaid Drug Rebate Program, which was also the subject of litigation that the Company filed against the Agency. The SEC issued subsequent subpoenas on January 7, 2022 and September 28, 2022, requesting additional documents from the Company. In connection with the investigation, on January 13, 2023, the SEC staff issued Wells Notices to the Company and individuals, including certain of its current and former executive officers, who were employed during 2019 (collectively, the “Individuals”). The notices indicate that the SEC staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege violations of the federal securities laws, and against the Individuals that would allege violations of the federal securities laws and/or aiding and abetting violations of the federal securities laws. The recommendation as to the Company may involve an injunction, a cease-and-desist order and/or other appropriate relief. The actions recommended by the SEC staff would allege, among other things, that (a) the Company improperly omitted to disclose the dispute with the Agency prior to the litigation filed by the Company in federal court on May 21, 2019, and (b) the Company’s disclosure of the civil investigative demand received from the U.S. Attorney’s Office for the District of Massachusetts in January 2019 (“Boston CID”) should have stated that the Boston CID related to the Company’s dispute with the Agency. A Wells Notice is neither a formal charge of wrongdoing nor a final determination that the recipient has violated any law. Under the SEC procedures, a recipient of a Wells Notice has an opportunity to respond and make a submission to the SEC staff setting forth the recipient’s interests and position in regard to the subject matter of the investigation. The Company believes that it has complied with all applicable laws and regulations, and it has provided a submission explaining the Company’s position and its belief that no enforcement action is warranted or appropriate. The Company understands that the Individuals have provided similar submissions to the SEC staff. The outcome of this matter is uncertain, and as a result, the Company is unable to estimate the potential exposure associated with this matter. Environmental Remediation and Litigation Proceedings The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites, including those described below. The ultimate cost of site cleanup and timing of future cash outlays is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. The Company concluded that, as of March 31, 2023 (Successor), it was probable that it would incur remediation costs in the range of $18.1 million to $48.1 million. The Company also concluded that, as of March 31, 2023 (Successor), the best estimate within this range was $36.5 million, of which $0.9 million was included in accrued and other current liabilities and the remainder was included in environmental liabilities on the unaudited condensed consolidated balance sheet as of March 31, 2023 (Successor). While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows. Lower Passaic River, New Jersey . The Company and approximately 70 other companies ("Cooperating Parties Group" or "CPG") are parties to a May 2007 Administrative Order on Consent with the Environmental Protection Agency ("EPA") to perform a remedial investigation and feasibility study ("RI/FS") of the 17-mile stretch known as the Lower Passaic River Study Area (“River”). The Company's potential liability stems from former operations at Lodi and Belleville, New Jersey (the “Lodi facility” and the “Belleville facility” respectively). In April 2014, the EPA issued a revised Focused Feasibility Study ("FFS"), with remedial alternatives to address cleanup of the lower 8-mile stretch of the River. The EPA estimated the cost for the remediation alternatives ranged from $365.0 million to $3.2 billion and the EPA's preferred approach had an estimated cost of $1.7 billion. In April 2015, the CPG presented a draft of the RI/FS of the River to the EPA that included alternative remedial actions for the entire 17-mile stretch of the River. In March 2016, the EPA issued the Record of Decision ("ROD(s)") for the lower 8 miles of the River with a slight modification on its preferred approach and a revised estimated cost of $1.38 billion. In October 2016, the EPA announced that Occidental Chemicals Corporation had entered into an agreement to develop the remedial design. In August 2018, the EPA finalized a buyout offer of $280,600 with the Company, limited to its former Lodi facility, for the lower 8 miles of the River. In September 2021, the EPA issued the ROD for the upper 9 miles of the River selecting source control as the remedy for the upper 9 miles with an estimated cost of $441.0 million. In September 2022, the Company entered into a conditional $0.3 million Early Cash-Out Consent Decree (“CD”) with the EPA as a buyout for its portion of the upper part of the River related to its former Lodi facility; finalization of the CD is subject to the EPA approval following the public comment period that ended March 2023. The portion of the liability related to the Belleville facility was discharged against the Company as a result of the Plan. Any reserves associated with this contingency were included in LSTC as of the Effective Date, and any related liabilities were discharged under the Bankruptcy Code. As of March 31, 2023, the Company estimated that its remaining liability related to the River was $21.0 million, which was included within environmental liabilities on the unaudited condensed consolidated balance sheet as of March 31, 2023 (Successor). Despite the issuance of the revised FFS and the RODs for both the lower and upper River by the EPA, the RI/FS by the CPG, and the cash out settlement by the EPA, there are many uncertainties associated with the final agreed-upon remediation, potential future liabilities and the Company's allocable share of the remediation. Given those uncertainties, the amounts accrued may not be indicative of the amounts for which the Company may be ultimately responsible and will be refined as the remediation progresses. Bankruptcy Litigation and Appeals First Lien Noteholder Matters. The Plan proposed to reinstate the issuers' existing 10.00% First Lien Senior Secured Notes due 2025 ("Existing First Lien Notes") in an aggregate principal amount of $495.0 million and the note documents relating thereto. Certain holders of the Existing First Lien Notes and the trustee in respect thereof (collectively, the "Noteholder Parties"), objected to the proposed reinstatement, arguing, among other things, that the Company was required to pay a significant make-whole premium as a condition to reinstatement of the Existing First Lien Notes. In the course of confirming the Plan, the Bankruptcy Court overruled these objections. On March 30, 2022, the Noteholder Parties appealed the confirmation order's approval of the reinstatement of the Existing First Lien Notes to the United States District Court for the District of Delaware. The Company and the Existing First Lien Notes Trustee reached an agreement to hold the trustee's appeal in abeyance, to be determined by the result of the holders' appeals, subject to certain conditions, which was approved by the District Court. Briefing on the merits of the Noteholder Parties' appeals was completed on July 1, 2022. On the same date, the Company moved to dismiss the Noteholder Parties' appeals as equitably moot. Briefing on the motion was completed on August 5, 2022 and supplemental declarations have been filed in the appeal. Oral argument was held on the Noteholder Parties' appeals on May 5, 2023, and the court took the matter under advisement. At this stage, the Company is not able to reasonably estimate the expected amount or range of cost or any loss associated with these appeals. The Company will continue to vigorously defend the Plan. Sanofi. On October 12, 2021, in the Company's bankruptcy, sanofi-aventis U.S. LLC ("Sanofi") filed a motion asking the Bankruptcy Court for an order determining that, under the Bankruptcy Code, the Company could not discharge alleged royalty obligations owed to Sanofi under an asset purchase agreement through which the Company acquired certain intellectual property from Sanofi's predecessor ("Sanofi Motion"). On November 8, 2021, the Bankruptcy Court denied the Sanofi Motion and ordered that any royalty obligations allegedly owed to Sanofi constitute prepetition unsecured claims that may be discharged under the Bankruptcy Code. On November 19, 2021, Sanofi appealed the Bankruptcy Court's ruling of the Sanofi Motion to the District Court. Briefing was completed on March 10, 2022 and the District Court affirmed on December 20, 2022, for which Sanofi filed a notice of appeal on January 17, 2023. Sanofi had also appealed the Bankruptcy Court's confirmation order, but pursuant to the terms of a settlement between Sanofi and the General Unsecured Claims Trustee appointed pursuant to the Plan, it is expected that Sanofi will dismiss its appeal of the confirmation order with prejudice in the near term. Banks et al. v. Cotter Corporation et al. v. Mallinckrodt LLC, et al. On January 29, 2023, the named plaintiffs in Banks et al. v. Cotter Corporation et al. v. Mallinckrodt LLC, et al. No. 20-CV-1227 (E.D. Mo.) filed a motion to amend their class-action petition to add Mallinckrodt LLC as a defendant. Mallinckrodt LLC filed a motion in the Bankruptcy Court to enjoin this petition on the grounds that these alleged claims were discharged pursuant to the Plan and confirmation order. On April 11, 2023, the court held oral argument on the motion to enjoin. Both motions remain pending until the Bankruptcy Court adjudicates the motion to enjoin. Under the confirmation order, any liability Mallinckrodt LLC may have in connection with the Banks litigation was discharged upon emergence from Chapter 11, with the limited exception of liability that is indemnified by the U.S. government. Other Matters The Company's legal proceedings and claims are further described within the notes to the financial statements included within the Company's Annual Report on Form 10-K.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	12. Financial Instruments and Fair Value Measurements Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows: Level 1— observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2— significant other observable inputs that are observable either directly or indirectly; and Level 3— significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period: March 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 38.2 $ 26.1 $ 12.1 $ — Equity securities 10.3 10.3 — — Interest rate cap 14.9 — 14.9 — $ 63.4 $ 36.4 $ 27.0 $ — Liabilities: Deferred compensation liabilities $ 19.0 $ — $ 19.0 $ — Contingent consideration liabilities 7.7 — — 7.7 $ 26.7 $ — $ 19.0 $ 7.7 December 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 36.6 $ 24.8 $ 11.8 $ — Equity securities 25.5 25.5 — — $ 62.1 $ 50.3 $ 11.8 $ — Liabilities: Deferred compensation liabilities $ 26.0 $ — $ 26.0 $ — Contingent consideration liabilities 7.3 — — 7.3 $ 33.3 $ — $ 26.0 $ 7.3 Debt and equity securities held in rabbi trusts. Debt securities held in rabbi trusts primarily consist of U.S. government and agency securities and corporate bonds. When quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in rabbi trusts primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges. Equity securities. Equity securities consist of shares in Silence Therapeutics plc and Panbela Therapeutics, Inc. for which quoted prices are available in an active market; therefore, these investments are classified as level 1 and are valued based on quoted market prices reported on internationally recognized securities exchanges. Interest rate cap. The Company is exposed to interest rate risk on its variable-rate debt. During the three months ended March 31, 2023, the Company entered into an interest rate cap agreement, which serves to reduce the volatility on future interest expense cash outflows. The interest rate cap agreement has a total notional value of $860.0 million with an upfront premium of $20.0 million and provides the Company with interest rate protection (i) for the period March 16, 2023 through July 19, 2023 to the extent that the one-month London Interbank Offered Rate ("LIBOR") exceeds 4.65%, and (ii) for the period July 20, 2023 through March 26, 2026 to the extent that the one-month Secured Overnight Financing Rate ("SOFR") exceeds 3.84%. The interest rate cap agreement qualifies as a cash flow hedge. The premium paid is recognized in income on a rational basis, and changes in the fair value of the interest rate cap are recorded within accumulated other comprehensive income ("AOCI") and are subsequently reclassed into interest expense in the period when the hedged interest affects earnings. The fair value of the interest rate cap is included in other assets on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2023 (Successor). The Company elected to use the income approach to value the interest rate cap derivative using observable Level 2 market expectations at the measurement date and standard valuation techniques to convert future amounts to a single present amount (discounted) reflecting current market expectations about those future amounts. Level 2 inputs for derivative valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically futures contracts) and inputs other than quoted prices that are observable such as LIBOR or SOFR rate curves, futures and volatilities. Mid-market pricing is used as a practical expedient in the fair value measurements. The Company recognized an unrealized loss of $5.0 million within AOCI during the three months ended March 31, 2023 (Successor), with $0.3 million being reclassified into earnings as a component of interest expense, net. It is expected that over the next 12 months, $6.7 million of the estimated losses in AOCI will be recognized into interest expense, net. The cash payment of the $20.0 million premium and other corresponding activity related to the interest rate cap were reflected as cash flows from operating activities in the unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2023 (Successor). Deferred compensation liabilities. The Company maintains a non-qualified deferred compensation plan in the U.S., which permits eligible employees of the Company to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The recordkeeping accounts generally correspond to the funds offered in the Company's U.S. tax-qualified defined contribution retirement plan and the account balance fluctuates with the investment returns on those funds. Contingent consideration liabilities. In accordance with the Plan and the Scheme of Arrangement, the Company will provide consideration for a contingent value right ("CVR") associated with Terlivaz ® primarily in the form of the achievement of a cumulative net sales milestone. The Company assesses the likelihood and timing of making such payments at each balance sheet date. The fair value of the contingent payment was measured based on the net present value of a probability-weighted assessment. The Company determined the fair value of the Terlivaz CVR as of March 31, 2023 (Successor) and December 30, 2022 (Successor) to be $7.7 million and $7.3 million, respectively. Financial Instruments Not Measured at Fair Value The following methods and assumptions were used by the Company in estimating fair values for financial instruments not measured at fair value as of March 31, 2023 (Successor) and December 30, 2022 (Successor): • The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash was equivalent to its carrying value of $56.9 million and $57.2 million as of March 31, 2023 (Successor) and December 30, 2022 (Successor) (level 1), respectively. • The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of $46.4 million and $46.7 million as of March 31, 2023 (Successor) and December 30, 2022 (Successor), respectively. These contracts are included in other assets on the unaudited condensed consolidated balance sheets. • The Company's 10.00% and 11.50% first and second lien senior secured notes are classified as level 1, as quoted prices are available in an active market for these notes. Since quoted market prices for the Company's term loans are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period: Successor March 31, 2023 December 30, 2022 Carrying Fair Carrying Fair Level 1: 10.00% first lien senior secured notes due April 2025 $ 478.0 $ 415.6 $ 475.9 $ 425.9 10.00% second lien senior secured notes due April 2025 249.8 222.1 242.2 216.8 11.50% first lien senior secured notes due December 2028 650.0 536.6 650.0 552.6 10.00% second lien senior secured notes due June 2029 179.8 192.0 175.5 176.7 Level 2: 2017 Replacement Term loan due September 2027 1,221.4 1,005.3 1,222.1 1,037.8 2018 Replacement Term loan due September 2027 326.6 262.6 326.9 274.8 Total Debt $ 3,105.6 $ 2,634.2 $ 3,092.6 $ 2,684.6 Concentration of Credit and Other Risks Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of accounts receivable. The Company generally does not require collateral from customers. A portion of the Company's accounts receivable outside the U.S. includes sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies. The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales: Successor Predecessor Three Months Three Months FFF Enterprises, Inc. 18.8 % * CuraScript, Inc. * 26.0 % * Net sales to this distributor was less than 10.0% of the Company's total net sales for the respective periods presented above. The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period: Successor March 31, December 30, AmerisourceBergen Corporation 26.1 % 23.3 % McKesson Corporation 19.0 17.3 FFF Enterprises, Inc. * 16.2 *Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above. The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales: Successor Predecessor Three Months Three Months INOmax 19.5 % 20.2 % Acthar Gel 19.3 26.0 Therakos 13.8 12.2 APAP 10.9 * *Net sales attributable to this product was less than 10.0% of total net sales for the respective period presented above.

Segment Data

Segment Data	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Data	13. Segment Data The Company operates in two reportable segments, which are further described below: • Specialty Brands includes innovative specialty pharmaceutical brands; and • Specialty Generics includes niche specialty generic drugs and APIs. Management measures and evaluates the Company's operating segments based on segment net sales and operating income. Management excludes corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management and the chief operating decision maker evaluate the operating results of the segments excluding such items. These items may include, but are not limited to, depreciation and amortization, share-based compensation, net restructuring charges, non-restructuring impairment charges and separation costs. Although these amounts are excluded from segment operating income, as applicable, they are included in reported consolidated operating loss and are reflected in the reconciliations presented below. Selected information by reportable segment was as follows: Successor Predecessor Three Months Three Months Net sales: Specialty Brands $ 252.0 $ 339.4 Specialty Generics 172.6 151.5 Net sales $ 424.6 $ 490.9 Operating income (loss): Specialty Brands $ 32.4 $ 164.8 Specialty Generics 32.8 34.4 Segment operating income 65.2 199.2 Unallocated amounts: Corporate and unallocated expenses (1) (14.0) (32.8) Depreciation and amortization (145.1) (177.2) Share-based compensation (2.6) (1.2) Restructuring charges, net (1.2) (6.8) Separation costs (2) (4.9) (2.0) Operating loss $ (102.6) $ (20.8) (1) Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments. (2) Represents costs included in selling, general and administrative expenses, primarily related to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence. Net sales by product family within the Company's reportable segments were as follows: Successor Predecessor Three Months Three Months Acthar Gel $ 82.0 $ 127.7 INOmax 82.7 99.0 Therakos 58.7 59.9 Amitiza (1) 24.5 47.7 Terlivaz 2.2 — Other 1.9 5.1 Specialty Brands 252.0 339.4 Opioids 62.2 50.0 ADHD 22.4 10.8 Addiction treatment 15.6 15.9 Other 1.8 2.8 Generics 102.0 79.5 Controlled substances 18.5 20.4 APAP 46.4 46.3 Other 5.7 5.3 API 70.6 72.0 Specialty Generics 172.6 151.5 Net sales $ 424.6 $ 490.9 (1) Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Commitments and Contingencies Certain litigation matters occurred on, or prior to, March 31, 2023 (Successor), but had subsequent updates through the issuance of this report. See further discussion in Note 11.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Sales Reserves Rollforward	The following table reflects activity in the Company's sales reserve accounts: Rebates and Chargebacks (1) Product Returns Other Sales Deductions Total Balance as of December 31, 2021 (Predecessor) $ 241.8 $ 21.5 $ 9.5 $ 272.8 Provisions 370.8 2.4 9.7 382.9 Payments or credits (412.0) (4.3) (10.0) (426.3) Balance as of April 1, 2022 (Predecessor) $ 200.6 $ 19.6 $ 9.2 $ 229.4 Balance as of December 30, 2022 (Successor) $ 265.3 $ 16.0 $ 12.7 $ 294.0 Provisions 355.6 3.2 9.5 368.3 Payments or credits (404.3) (4.0) (15.0) (423.3) Balance as of March 31, 2023 (Successor) $ 216.6 $ 15.2 $ 7.2 $ 239.0
Disaggregation of Revenue	Product sales transferred to customers at a point in time and over time were as follows: Successor Predecessor Three Months Three Months Product sales transferred at a point in time 80.2 % 79.5 % Product sales transferred over time 19.8 20.5 Successor Predecessor Three Months Three Months Royalty revenue $ 3.4 $ 20.0
Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment	The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of March 31, 2023 (Successor): Remainder of Fiscal 2023 $ 56.6 Fiscal 2024 37.7 Fiscal 2025 13.2 Thereafter 0.2

Restructuring and Related Cha_2

Restructuring and Related Charges (Tables)	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Charges by Segment	Net restructuring and related charges by segment were as follows: Successor Predecessor Three Months Three Months Specialty Generics $ — $ 3.5 Corporate 1.9 3.3 Restructuring and related charges, net 1.9 6.8 Less: accelerated depreciation (0.7) — Restructuring charges, net $ 1.2 $ 6.8
Schedule of Net Restructuring and Related Charges	Net restructuring and related charges by program were comprised of the following: Successor Predecessor Three Months Three Months 2018 Program $ 1.9 $ 6.8 Less: non-cash charges, including accelerated depreciation (0.8) (2.1) Total charges expected to be settled in cash $ 1.1 $ 4.7
Schedule of Restructuring Reserves Reconciliation by Program	The following table summarizes cash activity for restructuring reserves for the 2018 Program, which primarily related to employee severance and benefits: 2018 Program Balance as of December 30, 2022 (Successor) $ 4.6 Charges from continuing operations 1.2 Changes in estimate from continuing operations (0.1) Cash payments (4.2) Balance as of March 31, 2023 (Successor) $ 1.5
Schedule of Restructuring Charges Incurred Cumulative to Date	As of March 31, 2023 (Successor), net restructuring and related charges incurred cumulative to date for the 2018 Program were as follows: Successor Predecessor Specialty Brands $ — $ 3.1 Specialty Generics 0.8 18.5 Corporate 13.2 84.0 $ 14.0 $ 105.6

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The Company's income tax expense (benefit) was as follows: Successor Predecessor Three Months Three Months Current tax expense (benefit) $ 2.6 $ (5.0) Deferred tax benefit (33.4) (0.9) Income tax benefit $ (30.8) $ (5.9)

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Earnings per Share	The weighted-average number of shares outstanding used in the computations of both basic and diluted loss per share were as follows ( in millions ): Successor Predecessor Three Months Three Months Basic and diluted 13.2 84.7

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory, Net [Abstract]
Schedule of Inventories	Inventories were comprised of the following at the end of each period: Successor March 31, December 30, Raw materials and supplies $ 89.9 $ 80.2 Work in process 523.3 552.1 Finished goods 282.2 315.3 $ 895.4 $ 947.6

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment
Property, Plant and Equipment	The gross carrying amount and accumulated depreciation of property, plant and equipment were comprised of the following at the end of each period: Successor March 31, December 30, Property, plant and equipment, gross $ 492.5 $ 485.0 Less: accumulated depreciation (38.1) (27.4) Property, plant and equipment, net $ 454.4 $ 457.6
Depreciation of Fixed Assets	Depreciation expense was as follows: Successor Predecessor Three Months Three Months Depreciation expense $ 11.9 $ 22.1

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets were comprised of the following at the end of each period: Successor March 31, 2023 December 30, 2022 Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Completed technology $ 3,041.2 $ 451.9 $ 3,041.2 $ 318.7 Non-Amortizable: In-process research and development 121.3 121.3
Intangible Asset Amortization Expense	Intangible asset amortization expense was as follows: Successor Predecessor Three Months Three Months Amortization expense $ 133.2 $ 155.1
Schedule of Future Amortization Expense, Intangible Assets	The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows: Successor Remainder of Fiscal 2023 $ 376.0 Fiscal 2024 446.1 Fiscal 2025 385.1 Fiscal 2026 337.5 Fiscal 2027 284.4

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt including Capital Lease Obligation	Debt was comprised of the following at the end of each period: Successor March 31, 2023 December 30, 2022 Principal Carrying Value Unamortized Discount and Debt Issuance Costs Principal Carrying Value Unamortized Discount and Debt Issuance Costs Current maturities of long-term debt: 2017 Replacement Term loan due September 2027 $ 34.8 $ 34.8 $ — $ 34.8 $ 34.8 $ — 2018 Replacement Term loan due September 2027 9.3 9.3 — 9.3 9.3 — Total current debt 44.1 44.1 — 44.1 44.1 — Long-term debt: 10.00% first lien senior secured notes due April 2025 495.0 478.0 — 495.0 475.9 — 10.00% second lien senior secured notes due April 2025 321.9 249.8 — 321.9 242.2 — 2017 Replacement Term loan due September 2027 1,330.6 1,186.6 — 1,339.3 1,187.3 — 2018 Replacement Term loan due September 2027 353.2 317.3 — 355.5 317.6 — 11.50% first lien senior secured notes due December 2028 650.0 650.0 19.9 650.0 650.0 20.8 10.00% second lien senior secured notes due June 2029 328.3 179.8 — 328.3 175.5 — Total long-term debt 3,479.0 3,061.5 19.9 3,490.0 3,048.5 20.8 Total debt $ 3,523.1 $ 3,105.6 $ 19.9 $ 3,534.1 $ 3,092.6 $ 20.8
Schedule of Applicable Interest Rate on Variable-rate Debt	As of March 31, 2023 (Successor), the applicable interest rate and outstanding principal on the Company's debt instruments were as follows: Applicable Interest Rate Outstanding Principal Fixed-rate instruments 10.54 % $ 1,795.2 2017 Replacement Term Loan due September 2027 (1) 9.94 1,365.4 2018 Replacement Term Loan due September 2027 (1) 10.19 362.5

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period: March 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 38.2 $ 26.1 $ 12.1 $ — Equity securities 10.3 10.3 — — Interest rate cap 14.9 — 14.9 — $ 63.4 $ 36.4 $ 27.0 $ — Liabilities: Deferred compensation liabilities $ 19.0 $ — $ 19.0 $ — Contingent consideration liabilities 7.7 — — 7.7 $ 26.7 $ — $ 19.0 $ 7.7 December 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 36.6 $ 24.8 $ 11.8 $ — Equity securities 25.5 25.5 — — $ 62.1 $ 50.3 $ 11.8 $ — Liabilities: Deferred compensation liabilities $ 26.0 $ — $ 26.0 $ — Contingent consideration liabilities 7.3 — — 7.3 $ 33.3 $ — $ 26.0 $ 7.3
Schedule of Carrying Amount and Fair Value of Long-term Debt	The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period: Successor March 31, 2023 December 30, 2022 Carrying Fair Carrying Fair Level 1: 10.00% first lien senior secured notes due April 2025 $ 478.0 $ 415.6 $ 475.9 $ 425.9 10.00% second lien senior secured notes due April 2025 249.8 222.1 242.2 216.8 11.50% first lien senior secured notes due December 2028 650.0 536.6 650.0 552.6 10.00% second lien senior secured notes due June 2029 179.8 192.0 175.5 176.7 Level 2: 2017 Replacement Term loan due September 2027 1,221.4 1,005.3 1,222.1 1,037.8 2018 Replacement Term loan due September 2027 326.6 262.6 326.9 274.8 Total Debt $ 3,105.6 $ 2,634.2 $ 3,092.6 $ 2,684.6
Schedules of Concentration of Risk	The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales: Successor Predecessor Three Months Three Months FFF Enterprises, Inc. 18.8 % * CuraScript, Inc. * 26.0 % * Net sales to this distributor was less than 10.0% of the Company's total net sales for the respective periods presented above. The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period: Successor March 31, December 30, AmerisourceBergen Corporation 26.1 % 23.3 % McKesson Corporation 19.0 17.3 FFF Enterprises, Inc. * 16.2 *Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above. The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales: Successor Predecessor Three Months Three Months INOmax 19.5 % 20.2 % Acthar Gel 19.3 26.0 Therakos 13.8 12.2 APAP 10.9 * *Net sales attributable to this product was less than 10.0% of total net sales for the respective period presented above.

Segment Data (Tables)

Segment Data (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information by Reportable Segment	Selected information by reportable segment was as follows: Successor Predecessor Three Months Three Months Net sales: Specialty Brands $ 252.0 $ 339.4 Specialty Generics 172.6 151.5 Net sales $ 424.6 $ 490.9 Operating income (loss): Specialty Brands $ 32.4 $ 164.8 Specialty Generics 32.8 34.4 Segment operating income 65.2 199.2 Unallocated amounts: Corporate and unallocated expenses (1) (14.0) (32.8) Depreciation and amortization (145.1) (177.2) Share-based compensation (2.6) (1.2) Restructuring charges, net (1.2) (6.8) Separation costs (2) (4.9) (2.0) Operating loss $ (102.6) $ (20.8) (1) Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments. (2) Represents costs included in selling, general and administrative expenses, primarily related to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.
Schedule of Net Sales from External Customers by Products	Net sales by product family within the Company's reportable segments were as follows: Successor Predecessor Three Months Three Months Acthar Gel $ 82.0 $ 127.7 INOmax 82.7 99.0 Therakos 58.7 59.9 Amitiza (1) 24.5 47.7 Terlivaz 2.2 — Other 1.9 5.1 Specialty Brands 252.0 339.4 Opioids 62.2 50.0 ADHD 22.4 10.8 Addiction treatment 15.6 15.9 Other 1.8 2.8 Generics 102.0 79.5 Controlled substances 18.5 20.4 APAP 46.4 46.3 Other 5.7 5.3 API 70.6 72.0 Specialty Generics 172.6 151.5 Net sales $ 424.6 $ 490.9 (1) Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.

Background and Basis of Prese_2

Background and Basis of Presentation Background and Basis of Presentation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Schedule of Basis of Preperation [Line Items]
Cash Paid, Reorganization items	$ 9.4	$ 79.1

Revenue from Contracts with C_3

Revenue from Contracts with Customers Future Performance Obligations (Details) $ in Millions	Mar. 31, 2023 USD ($)
Remainder of Fiscal 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 56.6
Fiscal 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	37.7
Fiscal 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	13.2
Thereafter
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 0.2

Revenue from Contracts with C_4

Revenue from Contracts with Customers (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022	Dec. 30, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue Reserves	$ 239	$ 229.4	$ 294	$ 272.8
Revenue Reserve Provision	368.3	382.9
Revenue Reserve Payments or Credits	(423.3)	(426.3)
Net sales	424.6	$ 490.9
Accrued Medicaid	58.9		89.3
Accrued rebates	$ 44.6		55.3
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue	80.20%	79.50%
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue	19.80%	20.50%
Royalty [Member]
Disaggregation of Revenue [Line Items]
Net sales	$ 3.4	$ 20
Rebates and Chargebacks [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	216.6	200.6	265.3	241.8
Revenue Reserve Provision	355.6	370.8
Revenue Reserve Payments or Credits	(404.3)	(412)
Allowance for Sales Returns [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	15.2	19.6	16	21.5
Revenue Reserve Provision	3.2	2.4
Revenue Reserve Payments or Credits	(4)	(4.3)
Other Sales Deductions [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	7.2	9.2	$ 12.7	$ 9.5
Revenue Reserve Provision	9.5	9.7
Revenue Reserve Payments or Credits	$ (15)	$ (10)

Restructuring and Related Cha_3

Restructuring and Related Charges (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022	Dec. 01, 2021	Feb. 01, 2018
Restructuring Cost and Reserve
Restructuring charges, net	$ 1.2	$ 6.8
Restructuring Fiscal 2018 Plan | Minimum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost				$ 100
Restructuring Fiscal 2018 Plan | Maximum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost				$ 125
Restructuring Fiscal 2021 Plan | Minimum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost			$ 50
Restructuring Fiscal 2021 Plan | Maximum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost			$ 100

Restructuring and Related Cha_4

Restructuring and Related Charges (Schedule of Restructuring and Related Charges by Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 1.9	$ 6.8
Restructuring and Related Cost, Accelerated Depreciation	(0.7)	0
Restructuring charges, net	1.2	6.8
Specialty Generics
Restructuring Cost and Reserve
Restructuring and related charges, net	0	3.5
Corporate
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 1.9	$ 3.3

Restructuring and Related Cha_5

Restructuring and Related Charges (Schedule of Net Restructuring and Related Charges) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 1.9	$ 6.8
Restructuring and Related Costs, Non-cash Charges, Including Accelerated Depreciation	(0.8)	(2.1)
Total charges expected to be settled in cash	1.1	4.7
Restructuring Fiscal 2018 Plan
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 1.9	$ 6.8

Restructuring and Related Cha_6

Restructuring and Related Charges (Schedule of Restructuring Reserves by Type of Cost) (Details) - Continuing Operations - Restructuring Fiscal 2018 Plan $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 4.6
Charges from continuing operations	1.2
Changes in estimate from continuing operations	(0.1)
Cash payments	(4.2)
Ending Balance	$ 1.5

Restructuring and Related Cha_7

Restructuring and Related Charges (Schedule of Restructuring Charges Incurred Cumulative to Date) (Details) - Restructuring Fiscal 2018 Plan - USD ($) $ in Millions	Mar. 31, 2023	Jun. 16, 2022
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	$ 14	$ 105.6
Specialty Brands
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	0	3.1
Specialty Generics
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	0.8	18.5
Corporate
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	$ 13.2	$ 84

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022	Dec. 30, 2022
Income Taxes [Line Items]
Income tax benefit	$ (30.8)	$ (5.9)
Effective tax rate	11%	4.70%
Current Income Tax Expense (Benefit)	$ 2.6	$ (5)
Deferred Income Tax Expense (Benefit)	(33.4)	(0.9)
Unrecognized tax benefits	24.8
Increase (Decrease) Tax Expense (Benefit), Change in Operating Income	27.4	4.8
Increase (Decrease), Tax Expense (Benefit), CARES Act	(1.3)	(0.8)
Increase (Decrease), Income Tax Expense (Benefit), Separation Costs, Reorganization Items, and Restructuring Charges	2.1	1.9
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	0	0.6
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(280.1)	(126.1)
Proceeds from Income Tax Refunds	136.3
Interest accrued on unrecognized tax benefits	3.1		$ 2.8
Income Taxes Paid		$ 2.7
CARES Act [Member]
Income Taxes [Line Items]
Proceeds from Income Tax Refunds	139.3
Operational activity
Income Taxes [Line Items]
Proceeds from Income Tax Refunds	$ 3

Earnings per Share (Details)

Earnings per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	5.1
Weighted-average shares outstanding - basic (in shares)	13.2	84.7
Weighted-average shares outstanding - diluted (in shares)	13.2	84.7

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022
Raw materials and supplies	$ 89.9	$ 80.2
Work in process	523.3	552.1
Finished goods	282.2	315.3
Inventory, Net, Total	$ 895.4	$ 947.6

Property, Plant and Equipment_2

Property, Plant and Equipment (Schedule of Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022
Property, Plant and Equipment
Property, plant and equipment, gross	$ 492.5	$ 485
Less: accumulated depreciation	(38.1)	(27.4)
Property, plant and equipment, net	$ 454.4	$ 457.6

Property, Plant and Equipment D

Property, Plant and Equipment Depreciation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Property, Plant and Equipment
Depreciation	$ 11.9	$ 22.1
Depreciation	$ 11.9	$ 22.1

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022	Dec. 30, 2022
Schedule of Intangible Asset by Major Class [Line Items]
Intangible assets, net	$ 2,710.6		$ 2,843.8
Amortization of Intangible Assets	$ 133.2	$ 155.1
Loss from continuing operations	$ (18.93)	$ (1.42)
In-process Research and Development
Schedule of Intangible Asset by Major Class [Line Items]
Non-Amortizable intangible assets, gross	$ 121.3		121.3
Completed Technology
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	3,041.2		3,041.2
Accumulated amortization	$ 451.9		$ 318.7

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Schedule of Intangible Asset Amortization Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 133.2	$ 155.1

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Schedule of Future Amortization Expense, Intangible Assets) (Details) $ in Millions	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2023	$ 376
Fiscal 2024	446.1
Fiscal 2025	385.1
Fiscal 2026	337.5
Fiscal 2027	$ 284.4

Debt (Details)

Debt (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022	Jun. 16, 2022
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	$ 0	$ 0
Long-term Debt, Current Maturities	44.1	44.1
Long-term debt
Total Debt Issuance Costs	19.9	20.8
Total Debt	3,105.6	3,092.6
Debt Instrument, Face Amount	3,523.1	3,534.1
Long-term Debt	3,061.5	3,048.5
Debt Issuance Costs	19.9	20.8
Debt Instrument, Face Amount, Current Maturity	44.1	44.1
Debt Instrument, Face Amount, Noncurrent Maturity	3,479	3,490
10.00% Second Lien Senior Notes
Long-term debt
Long-term Debt	249.8	242.2
Debt Issuance Costs	0	0
Debt Instrument, Face Amount, Noncurrent Maturity	321.9	321.9
10.00% First Lien Senior Notes
Long-term debt
Debt Instrument, Face Amount			$ 495
Long-term Debt	478	475.9
Debt Issuance Costs	0	0
Debt Instrument, Face Amount, Noncurrent Maturity	495	495
2017 Replacement Term Loan
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0	0
Long-term Debt, Current Maturities	34.8	34.8
Long-term debt
Total Debt	1,221.4	1,222.1
Debt Instrument, Face Amount	1,365.4
Long-term Debt	1,186.6	1,187.3
Debt Issuance Costs	0	0
Debt Instrument, Face Amount, Current Maturity	34.8	34.8
Debt Instrument, Face Amount, Noncurrent Maturity	1,330.6	1,339.3
2018 Replacement Term Loan
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0	0
Long-term Debt, Current Maturities	9.3	9.3
Long-term debt
Total Debt	326.6	326.9
Debt Instrument, Face Amount	362.5
Long-term Debt	317.3	317.6
Debt Issuance Costs	0	0
Debt Instrument, Face Amount, Current Maturity	9.3	9.3
Debt Instrument, Face Amount, Noncurrent Maturity	353.2	355.5
Eleven Point Five Percent First Lien Senior Secured Notes
Long-term debt
Long-term Debt	650	650
Debt Issuance Costs	19.9	20.8
Debt Instrument, Face Amount, Noncurrent Maturity	650	650
Ten Point Zero Percent Second Lien Notes due 2029
Long-term debt
Long-term Debt	179.8	175.5
Debt Issuance Costs	0	0
Debt Instrument, Face Amount, Noncurrent Maturity	$ 328.3	$ 328.3

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022	Jun. 16, 2022
Debt Instrument
Debt Instrument, Face Amount	$ 3,523.1	$ 3,534.1
10.00% First Lien Senior Notes
Debt Instrument
Debt Instrument, Face Amount			$ 495
2017 Replacement Term Loan
Debt Instrument
Debt Instrument, Face Amount	1,365.4
2018 Replacement Term Loan
Debt Instrument
Debt Instrument, Face Amount	$ 362.5

Debt (Schedule of Applicable In

Debt (Schedule of Applicable Interest Rates on Variable-rate Debt) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Total Debt	$ 3,105.6	$ 3,092.6
Debt Instrument, Face Amount	$ 3,523.1	3,534.1
Fixed-rate instruments
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time	10.54%
Total Debt	$ 1,795.2
2017 Replacement Term Loan
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time	9.94%
Total Debt	$ 1,221.4	1,222.1
Debt Instrument, Face Amount	$ 1,365.4
2018 Replacement Term Loan
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time	10.19%
Total Debt	$ 326.6	$ 326.9
Debt Instrument, Face Amount	$ 362.5

Guarantees (Details)

Guarantees (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022
Others
Guarantor Obligations [Line Items]
Maximum future payments	$ 29.9
Asset Pledged as Collateral [Member]
Guarantor Obligations [Line Items]
Restricted Cash	37.4
Mallinckrodt Baker | Indemnification Agreement
Guarantor Obligations [Line Items]
Escrow Deposit	30
Mallinckrodt Baker | Indemnification Agreement | Other current and non-current assets
Guarantor Obligations [Line Items]
Escrow Deposit	$ 19.5	$ 19.3

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details)	May 01, 2007 Defendent	Mar. 31, 2023 USD ($)	Dec. 30, 2022 USD ($)	Sep. 09, 2022 USD ($)	Jun. 16, 2022 USD ($)	Sep. 28, 2021 USD ($)	Sep. 27, 2019 USD ($)	Aug. 07, 2018 USD ($)	Apr. 11, 2014 USD ($)
Loss Contingencies [Line Items]
Environmental liabilities		$ 36,500,000
Environmental liabilities, current		900,000
Environmental liabilities		35,600,000	$ 35,800,000
Debt Instrument, Face Amount		3,523,100,000	$ 3,534,100,000
Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Loss Contingency, Number of Defendants | Defendent	70
Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss							$ 1,380,000,000		$ 1,700,000,000
Loss Contingency, Settlement Agreement, Amount				$ 300,000				$ 280,600
Upper 9 Miles, Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss		21,000,000				$ 441,000,000
Minimum
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss		18,100,000
Minimum | Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss									365,000,000
Maximum
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss		$ 48,100,000
Maximum | Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss									$ 3,200,000,000
10.00% First Lien Senior Notes
Loss Contingencies [Line Items]
Debt Instrument, Face Amount					$ 495,000,000

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 13, 2023	Dec. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative, Notional Amount		$ 860
Derivative, Interest Rate Cap, Premium	$ 20
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax	0.3
Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Pretax, Accumulated Other Comprehensive Income (Loss)	5
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	6.7
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative, Cap Interest Rate		3.84%
London Interbank Offered Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative, Cap Interest Rate		4.65%
Level 3 | Other current and non-current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash surrender value of life insurance	46.4		$ 46.7
Indemnification Agreement | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Restricted Cash and Cash Equivalents	$ 56.9		$ 57.2

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022
Assets:
Other Assets, Fair Value Disclosure	$ 10.3	$ 25.5
Assets, Fair Value Disclosure	63.4	62.1
Liabilities:
Cash Flow Hedge Derivative Instrument Assets at Fair Value	14.9
Level 1 | Indemnification Agreement
Liabilities:
Restricted Cash and Cash Equivalents	56.9	57.2
Recurring
Assets:
Rabbi Trust Investments, Fair Value Disclosure	38.2	36.6
Liabilities:
Deferred Compensation Liability, Fair Value	19	26
Contingent consideration and acquired contingent liabilities	7.7	7.3
Total liabilities at fair value	26.7	33.3
Recurring | Level 1
Assets:
Rabbi Trust Investments, Fair Value Disclosure	26.1	24.8
Other Assets, Fair Value Disclosure	10.3	25.5
Assets, Fair Value Disclosure	36.4	50.3
Liabilities:
Deferred Compensation Liability, Fair Value	0	0
Contingent consideration and acquired contingent liabilities	0	0
Total liabilities at fair value	0	0
Cash Flow Hedge Derivative Instrument Assets at Fair Value	0
Recurring | Level 2
Assets:
Rabbi Trust Investments, Fair Value Disclosure	12.1	11.8
Other Assets, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	27	11.8
Liabilities:
Deferred Compensation Liability, Fair Value	19	26
Contingent consideration and acquired contingent liabilities	0	0
Total liabilities at fair value	19	26
Cash Flow Hedge Derivative Instrument Assets at Fair Value	14.9
Recurring | Level 3
Assets:
Rabbi Trust Investments, Fair Value Disclosure	0	0
Other Assets, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	0	0
Liabilities:
Deferred Compensation Liability, Fair Value	0	0
Contingent consideration and acquired contingent liabilities	7.7	7.3
Total liabilities at fair value	7.7	$ 7.3
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 0

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements (Schedule of Carrying Amount and Fair Value of Long-term Debt) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 30, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	$ 44.1	$ 44.1
Total debt, fair value	2,634.2	2,684.6
Long-term Debt	3,061.5	3,048.5
Total Debt	3,105.6	3,092.6
10.00% Second Lien Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Total debt, fair value	222.1	216.8
Long-term Debt	249.8	242.2
10.00% First Lien Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Total debt, fair value	415.6	425.9
Long-term Debt	478	475.9
Eleven Point Five Percent First Lien Senior Secured Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Total debt, fair value	536.6	552.6
Long-term Debt	650	650
Ten Point Zero Percent Second Lien Notes due 2029
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Total debt, fair value	192	176.7
Long-term Debt	179.8	175.5
2017 Replacement Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	34.8	34.8
Total debt, fair value	1,005.3	1,037.8
Long-term Debt	1,186.6	1,187.3
Total Debt	1,221.4	1,222.1
2018 Replacement Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	9.3	9.3
Total debt, fair value	262.6	274.8
Long-term Debt	317.3	317.6
Total Debt	$ 326.6	$ 326.9

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements (Schedules of Concentration of Risk) (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Apr. 01, 2022	Dec. 30, 2022
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | CuraScript, Inc
Concentration Risk
Concentration Risk, Percentage		26%
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | FFF Enterprises, Inc.
Concentration Risk
Concentration Risk, Percentage	18.80%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Amerisource Bergen Corporation [Member]
Concentration Risk
Concentration Risk, Percentage	26.10%		23.30%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | McKesson Corporation [Member]
Concentration Risk
Concentration Risk, Percentage	19%		17.30%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | FFF Enterprises, Inc.
Concentration Risk
Concentration Risk, Percentage			16.20%
Product Concentration Risk | Net Sales Attributable to Products | Acthar
Concentration Risk
Concentration Risk, Percentage	19.30%	26%
Product Concentration Risk | Net Sales Attributable to Products | Inomax
Concentration Risk
Concentration Risk, Percentage	19.50%	20.20%
Product Concentration Risk | Net Sales Attributable to Products | Therakos [Member]
Concentration Risk
Concentration Risk, Percentage	13.80%	12.20%
Product Concentration Risk | Net Sales Attributable to Products | APAP
Concentration Risk
Concentration Risk, Percentage	10.90%

Segment Data (Schedule of Segme

Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Net sales	$ 424.6	$ 490.9
Operating Income (Loss)	(102.6)	(20.8)
Depreciation and amortization	(133.2)	(155.1)
Employee Benefits and Share-based Compensation	(2.6)	(1.2)
Restructuring and related charges, net	(1.9)	(6.8)
Specialty Generics
Net sales	172.6	151.5
Restructuring and related charges, net	0	(3.5)
Corporate, Non-Segment
Corporate and unallocated expenses	(14)	(32.8)	[1]
Depreciation and amortization	(145.1)	(177.2)
Restructuring and related charges, net	(1.2)	(6.8)
Separation Costs	(4.9)	(2)	[2]
Operating Segments
Operating Income (Loss)	65.2	199.2
Operating Segments | Specialty Brands
Net sales	252	339.4
Operating Income (Loss)	32.4	164.8
Operating Segments | Specialty Generics
Net sales	172.6	151.5
Operating Income (Loss)	$ 32.8	$ 34.4
[1]Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.[2]Represents costs included in selling, general and administrative expenses, primarily related to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.

Segment Data (Schedule of Net S

Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Segment Reporting Information
Net sales	$ 424.6	$ 490.9
Specialty Brands | Operating Segments
Segment Reporting Information
Net sales	252	339.4
Specialty Generics
Segment Reporting Information
Net sales	172.6	151.5
Specialty Generics | Operating Segments
Segment Reporting Information
Net sales	172.6	151.5
Acthar | Specialty Brands
Segment Reporting Information
Net sales	82	127.7
Inomax | Specialty Brands
Segment Reporting Information
Net sales	82.7	99
Therakos immunotherapy | Specialty Brands
Segment Reporting Information
Net sales	58.7	59.9
Amitiza [Member] | Specialty Brands
Segment Reporting Information
Net sales	24.5	47.7
Other | Specialty Brands
Segment Reporting Information
Net sales	1.9	5.1
Opioids | Specialty Generics
Segment Reporting Information
Net sales	62.2	50
ADHD | Specialty Generics
Segment Reporting Information
Net sales	22.4	10.8
Addiction Treatment | Specialty Generics
Segment Reporting Information
Net sales	15.6	15.9
Other Generics | Specialty Generics
Segment Reporting Information
Net sales	1.8	2.8
Generics | Specialty Generics
Segment Reporting Information
Net sales	102	79.5
Controlled substances | Specialty Generics
Segment Reporting Information
Net sales	18.5	20.4
APAP | Specialty Generics
Segment Reporting Information
Net sales	46.4	46.3
Other API | Specialty Generics
Segment Reporting Information
Net sales	5.7	5.3
API | Specialty Generics
Segment Reporting Information
Net sales	70.6	72
Terlivaz | Specialty Brands
Segment Reporting Information
Net sales	$ 2.2	$ 0